The effect of ginseng in the treatment of brucellosis

Effectiveness of ginseng compared with gentamicin in the improvement of symptoms in patients with brucellosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201412219855N8

Enrollment

165

Registered

2015-01-10

Start date

2014-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis. Brucellosis

Interventions

Intervention 1: Intervention group 1: doxycycline 200 mg capsules daily (6 weeks) plus rifampin 600 mg capsules daily (6 weeks) plus Ginseng capsules 500 mg daily (1 week). Intervention 2: Intervent

Treatment - Drugs

Intervention group 1: doxycycline 200 mg capsules daily (6 weeks) plus rifampin 600 mg capsules daily (6 weeks) plus Ginseng capsules 500 mg daily (1 week)

Intervention group 2 capsules doxycycline 200 mg (6 weeks) plus rifampin 600 mg once daily (6 weeks) plus gentamicin 5 mg/kg per day (1 week)

Controls: doxycycline 200 mg capsules daily (6 weeks) plus rifampin 600 mg capsules daily (6 weeks)

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: age over 15 years; Wright titer at least 1/160 and 2ME 1/40; informed consent to participate in the study Exclusion criteria: history of brucellosis in the past 2 years; history of chronic brucellosis; pregnant women; having innate or acquired immunodeficiency; history of allergy to ginseng; local forms of brucellosis infection such as endocarditis, spondylitis, etc.; patients with advanced or chronic disease of heart, lung, liver and kidney

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Disappearance of fever. Timepoint: Days of 0, 3, 5, 7, 14, 21. Method of measurement: With thermometer.;Resolve of arthralgia. Timepoint: Days of 0, 3, 5, 7, 14, 21. Method of measurement: Questionnaire.;Constitutional symptoms. Timepoint: Days of 0, 3, 5, 7, 14, 21. Method of measurement: Questionnaire.;Decrease of CRP. Timepoint: Days of 0,7, 14, 21, 28, 42. Method of measurement: Latex agglutination test.	—

Measure

Time frame

Disappearance of fever. Timepoint: Days of 0, 3, 5, 7, 14, 21. Method of measurement: With thermometer.;Resolve of arthralgia. Timepoint: Days of 0, 3, 5, 7, 14, 21. Method of measurement: Questionnaire.;Constitutional symptoms. Timepoint: Days of 0, 3, 5, 7, 14, 21. Method of measurement: Questionnaire.;Decrease of CRP. Timepoint: Days of 0,7, 14, 21, 28, 42. Method of measurement: Latex agglutination test.

—

Secondary

Measure	Time frame
Treatment Failure. Timepoint: End of 6 weeks treatment. Method of measurement: No improvement in clinical symptoms and laboratory tests.;Relapse. Timepoint: Months of 3, 4, 5, 6, 7, 8. Method of measurement: ecurrence of clinical symptoms and laboratory tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Aliasghar Farazi

Arak University of Medical Sciences

farazialiasghar@yahoo.com+98 86341411

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026